BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38158497)

  • 21. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.
    Long GV; Luke JJ; Khattak MA; de la Cruz Merino L; Del Vecchio M; Rutkowski P; Spagnolo F; Mackiewicz J; Chiarion-Sileni V; Kirkwood JM; Robert C; Grob JJ; de Galitiis F; Schadendorf D; Carlino MS; Mohr P; Dummer R; Gershenwald JE; Yoon CH; Wu XL; Fukunaga-Kalabis M; Krepler C; Eggermont AMM; Ascierto PA;
    Lancet Oncol; 2022 Nov; 23(11):1378-1388. PubMed ID: 36265502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma.
    Wei X; Wu D; Li H; Zhang R; Chen Y; Yao H; Chi Z; Sheng X; Cui C; Bai X; Qi Z; Li K; Lan S; Chen L; Guo R; Yao X; Mao L; Lian B; Kong Y; Dai J; Tang B; Yan X; Wang X; Li S; Zhou L; Balch CM; Si L; Guo J
    Ann Surg Oncol; 2020 Sep; 27(9):3478-3485. PubMed ID: 32253677
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Male sex and Breslow thickness are important risk factors for recurrence of localized melanoma in Korean populations.
    Oh Y; Choi S; Cho MY; Nam KA; Shin SJ; Chang JS; Oh BH; Roh MR; Chung KY
    J Am Acad Dermatol; 2020 Oct; 83(4):1071-1079. PubMed ID: 31562946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mitotic rate in node-positive stage III melanoma: it might be as important a prognostic factor as node number.
    Tas F; Erturk K
    Jpn J Clin Oncol; 2021 May; 51(6):873-878. PubMed ID: 33758939
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Do Oncologic Outcomes From Head and Neck Versus Truncal and Extremity Melanoma Differ? A Single-Institution Single-Subspecialty Experience.
    Baecher KM; Turgeon MK; Medin CR; Mahendran G; Flakes TM; Delman KA; Lowe MC
    Am Surg; 2022 Mar; 88(3):480-488. PubMed ID: 34761683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Prognostic Markers in Stage IIIB Melanoma.
    Madu MF; Wouters MW; Klop WM; van der Hiel B; van de Wiel BA; Jóźwiak K; van der Hage JA; van Akkooi AC
    Ann Surg Oncol; 2016 Dec; 23(13):4195-4202. PubMed ID: 27380642
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Different mitotic rates are associated with different prognostic factors, relapses, and survival rates in melanoma.
    Tas F; Erturk K
    Int J Dermatol; 2022 Apr; 61(4):472-479. PubMed ID: 34633070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant nodal field radiation in resected Stage III melanoma: A single-centre retrospective study in Christchurch, New Zealand.
    Leong TW; McCook G; Frampton CM; Robinson BA; James ML
    J Med Imaging Radiat Oncol; 2022 Oct; 66(7):1003-1013. PubMed ID: 35642730
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Wide excision without radiation for desmoplastic melanoma.
    Arora A; Lowe L; Su L; Rees R; Bradford C; Cimmino VC; Chang AE; Johnson TM; Sabel MS
    Cancer; 2005 Oct; 104(7):1462-7. PubMed ID: 16080180
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Margins of excision for cutaneous melanoma of the eyelid skin: the Collaborative Eyelid Skin Melanoma Group Report.
    Esmaeli B; Youssef A; Naderi A; Ahmadi MA; Meyer DR; McNab A;
    Ophthalmic Plast Reconstr Surg; 2003 Mar; 19(2):96-101. PubMed ID: 12644753
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model.
    Eggermont AMM; Bellomo D; Arias-Mejias SM; Quattrocchi E; Sominidi-Damodaran S; Bridges AG; Lehman JS; Hieken TJ; Jakub JW; Murphree DH; Pittelkow MR; Sluzevich JC; Cappel MA; Bagaria SP; Perniciaro C; Tjien-Fooh FJ; Rentroia-Pacheco B; Wever R; van Vliet MH; Dwarkasing J; Meves A
    Eur J Cancer; 2020 Nov; 140():11-18. PubMed ID: 33032086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma.
    Wagner JD; Ranieri J; Evdokimow DZ; Logan T; Chuang TY; Johnson CS; Jung SH; Wenck S; Coleman JJ
    Plast Reconstr Surg; 2003 Aug; 112(2):486-97. PubMed ID: 12900606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRAF mutation correlates with worse local-regional control following radiation therapy in patients with stage III melanoma.
    Wolfe AR; Chablani P; Siedow MR; Miller ED; Walston S; Kendra KL; Wuthrick E; Williams TM
    Radiat Oncol; 2021 Sep; 16(1):181. PubMed ID: 34537078
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification.
    Ferris LK; Farberg AS; Middlebrook B; Johnson CE; Lassen N; Oelschlager KM; Maetzold DJ; Cook RW; Rigel DS; Gerami P
    J Am Acad Dermatol; 2017 May; 76(5):818-825.e3. PubMed ID: 28110997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stage-Specific Risk of Recurrence and Death From Melanoma in Denmark, 2008-2021: A National Observational Cohort Study of 25 720 Patients With Stage IA to IV Melanoma.
    Helvind NM; Brinch-Møller Weitemeyer M; Chakera AH; Hendel HW; Ellebæk E; Svane IM; Kjærskov MW; Bojesen S; Skyum H; Petersen SK; Bastholt L; Johansen C; Bidstrup PE; Hölmich LR
    JAMA Dermatol; 2023 Nov; 159(11):1213-1222. PubMed ID: 37650576
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy.
    Suciu S; Eggermont AMM; Lorigan P; Kirkwood JM; Markovic SN; Garbe C; Cameron D; Kotapati S; Chen TT; Wheatley K; Ives N; de Schaetzen G; Efendi A; Buyse M
    J Natl Cancer Inst; 2018 Jan; 110(1):. PubMed ID: 28922786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stage-specific disease recurrence and survival in localized and regionally advanced cutaneous melanoma.
    Leeneman B; Franken MG; Coupé VMH; Hendriks MP; Kruit W; Plaisier PW; van Ruth S; Verstijnen JAMC; Wouters MWJM; Blommestein HM; Uyl-de Groot CA
    Eur J Surg Oncol; 2019 May; 45(5):825-831. PubMed ID: 30765270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of prognostic factors and comorbidities on survival in older adults with stage I - III cutaneous melanoma in Southwest Finland: A register study.
    Mattila KE; Vihinen H; Heervä E; Nuotio MS; Vihinen P
    J Geriatr Oncol; 2024 Mar; 15(2):101701. PubMed ID: 38219332
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic significance of acral lentiginous histologic type in T1 melanoma.
    Mejbel HA; Torres-Cabala CA; Milton DR; Ivan D; Feldmeyer L; Namikawa K; Nagarajan P; Tetzlaff MT; Curry JL; Ross MI; Hwu WJ; Prieto VG; Aung PP
    Mod Pathol; 2021 Mar; 34(3):572-583. PubMed ID: 32759976
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sarcopenia as a prognostic factor among patients with stage III melanoma.
    Sabel MS; Lee J; Cai S; Englesbe MJ; Holcombe S; Wang S
    Ann Surg Oncol; 2011 Dec; 18(13):3579-85. PubMed ID: 21822551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.